Global Diabetes Insulin Pen

Diabetes Insulin Pen Comprehensive Study by Type (Disposable pen, Reusable pen, Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens}), Indication (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics, Others), End user (Geriatric population, Youth, Children) Players and Region - Global Market Outlook to 2027

Diabetes Insulin Pen Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Diabetes Insulin Pen Market Scope
Insulin pens make it easier to take insulin because they combine the medication and the syringe in one convenient unit. Insulin pens are preloaded with insulin, including premixed insulin. They're easy to use: just twist or snap on a new needle, dial a dose, inject the insulin, and dispose of the used needle in a needle-safe sharps container. Certain insulin pens are disposable, which means that once the insulin is gone or expired, the pen can be discarded, whereas other pens can be reused after a new insulin cartridge is inserted. Many brands offer color-coded pens with different designs to help consumers identify the type of insulin they are using at a glance. This reduces administration time and makes them more portable. Some new models come with a digital application.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledEli Lilly and Company (United States), Medtronic (Ireland), Novo Nordisk (Denmark), Sanofi (France), Becton, Dickinson and Company (United States), Biocon (India), Diamesco (South Korea), Emperra (Germany), Guangzhou Medsinglong Medical Equipment (China) and HK Zion Industry (China)
CAGR%


Major players have been investing in R&D and new product development due to the increasing number of diabetic 2 prevalence in patients. The Smartpen technology undertaken by a few major players has made them stand out in the market. Whereas the High cost of products has been holding the market growth as there are many substitute products which do cost less. The key players have been looking for mergers and acquisitions to have better products in the portfolio as well as due to high technological requirements it has made it a bit convenient for new players to enter the market.

Eli Lilly and Company (United States), Medtronic (Ireland), Novo Nordisk (Denmark), Sanofi (France), Becton, Dickinson and Company (United States), Biocon (India), Diamesco (South Korea), Emperra (Germany), Guangzhou Medsinglong Medical Equipment (China) and HK Zion Industry (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Jiangsu Delfu Medical Device (China), Owen Mumford (United Kingdom), Shanghai Umitai Medical Technology (China), SUN MEDICAL CO., LTD (Japan), Suzhou Peng Ye Medical Technology Co., Ltd. (China), Triones Technology (India) and Ypsomed (Switzerland).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Diabetes Insulin Pen market by Type and Region with country level break-up.

On the basis of geography, the market of Diabetes Insulin Pen has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.

Market Leaders and their expansionary development strategies
Novo Nordisk in December 2021 announced the acquisition of Dicerna Pharmaceuticals. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding.
In March 2022 Novo Nordisk launches the first smart insulin pens for NHS patients. The new devices NovoPen 6 and NovoPen Echo Plus – are insulin self-injection pens that record information such as when and how much insulin is administered, with the data uploaded to an app via near-field communication (NFC) link so it can be reviewed by the patients themselves and healthcare professionals.
In an effort to reduce the serious risk of infection spread through sharing of multi-dose diabetes pen devices intended for single patient use only, the U.S. Food and Drug Administration (FDA) is requiring additional label warnings prohibiting sharing of these injectable medicines. Insulin pens and pens for other injectable diabetes medicines should never be shared among patients, even if the needle is changed. Sharing pens can result in the spread of serious infections from one patient to another. To promote safe use, we are requiring that pens and packaging containing multiple doses of insulin and other injectable diabetes medicines display a warning label stating “For single patient use only.”

Diabetes Insulin Pen Market Dynamics:
AttributesDetails
Trends Influencing Market
  • Smart Pen Technology has Been Showing a Trending Impact on the Market.
Key Restraints
  • Higher Availability of Substitute Products.
Challenges
  • High Cost of Product has Been Holding the Market Growth.
Market Opportunities
  • Growing R&D for Diabetic Instruments and Support Will be developing more Opportunities.


Key Target Audience
Pharmaceutical companies, New Entrants and Investors, Legalized Cannabis Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Disposable pen
  • Reusable pen
  • Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens}
By Indication
  • Type 1 Diabetes
  • Type 2 Diabetes

By Distribution Channel
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Diabetes Clinics
  • Others

By End user
  • Geriatric population
  • Youth
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Diabetic 2 Prevalence has Been Rising the Need for Insulin Administration.
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Product has Been Holding the Market Growth.
    • 3.4. Market Trends
      • 3.4.1. Smart Pen Technology has Been Showing a Trending Impact on the Market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetes Insulin Pen, by Type, Indication, Distribution Channel, End user and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Diabetes Insulin Pen (Value)
      • 5.2.1. Global Diabetes Insulin Pen by: Type (Value)
        • 5.2.1.1. Disposable pen
        • 5.2.1.2. Reusable pen
        • 5.2.1.3. Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens}
      • 5.2.2. Global Diabetes Insulin Pen by: Indication (Value)
        • 5.2.2.1. Type 1 Diabetes
        • 5.2.2.2. Type 2 Diabetes
      • 5.2.3. Global Diabetes Insulin Pen by: Distribution Channel (Value)
        • 5.2.3.1. Online Pharmacies
        • 5.2.3.2. Hospital Pharmacies
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Diabetes Clinics
        • 5.2.3.5. Others
      • 5.2.4. Global Diabetes Insulin Pen by: End user (Value)
        • 5.2.4.1. Geriatric population
        • 5.2.4.2. Youth
        • 5.2.4.3. Children
      • 5.2.5. Global Diabetes Insulin Pen Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Diabetes Insulin Pen: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Becton, Dickinson and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biocon (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Diamesco (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Emperra (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Guangzhou Medsinglong Medical Equipment (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. HK Zion Industry (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Diabetes Insulin Pen Sale, by Type, Indication, Distribution Channel, End user and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Diabetes Insulin Pen (Value)
      • 7.2.1. Global Diabetes Insulin Pen by: Type (Value)
        • 7.2.1.1. Disposable pen
        • 7.2.1.2. Reusable pen
        • 7.2.1.3. Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens}
      • 7.2.2. Global Diabetes Insulin Pen by: Indication (Value)
        • 7.2.2.1. Type 1 Diabetes
        • 7.2.2.2. Type 2 Diabetes
      • 7.2.3. Global Diabetes Insulin Pen by: Distribution Channel (Value)
        • 7.2.3.1. Online Pharmacies
        • 7.2.3.2. Hospital Pharmacies
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Diabetes Clinics
        • 7.2.3.5. Others
      • 7.2.4. Global Diabetes Insulin Pen by: End user (Value)
        • 7.2.4.1. Geriatric population
        • 7.2.4.2. Youth
        • 7.2.4.3. Children
      • 7.2.5. Global Diabetes Insulin Pen Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetes Insulin Pen: by Type(USD Million)
  • Table 2. Diabetes Insulin Pen Disposable pen , by Region USD Million (2016-2021)
  • Table 3. Diabetes Insulin Pen Reusable pen , by Region USD Million (2016-2021)
  • Table 4. Diabetes Insulin Pen Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens} , by Region USD Million (2016-2021)
  • Table 5. Diabetes Insulin Pen: by Indication(USD Million)
  • Table 6. Diabetes Insulin Pen Type 1 Diabetes , by Region USD Million (2016-2021)
  • Table 7. Diabetes Insulin Pen Type 2 Diabetes , by Region USD Million (2016-2021)
  • Table 8. Diabetes Insulin Pen: by Distribution Channel(USD Million)
  • Table 9. Diabetes Insulin Pen Online Pharmacies , by Region USD Million (2016-2021)
  • Table 10. Diabetes Insulin Pen Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 11. Diabetes Insulin Pen Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 12. Diabetes Insulin Pen Diabetes Clinics , by Region USD Million (2016-2021)
  • Table 13. Diabetes Insulin Pen Others , by Region USD Million (2016-2021)
  • Table 14. Diabetes Insulin Pen: by End user(USD Million)
  • Table 15. Diabetes Insulin Pen Geriatric population , by Region USD Million (2016-2021)
  • Table 16. Diabetes Insulin Pen Youth , by Region USD Million (2016-2021)
  • Table 17. Diabetes Insulin Pen Children , by Region USD Million (2016-2021)
  • Table 18. South America Diabetes Insulin Pen, by Country USD Million (2016-2021)
  • Table 19. South America Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 20. South America Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 21. South America Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 22. South America Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 23. Brazil Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 24. Brazil Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 25. Brazil Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 26. Brazil Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 27. Argentina Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 28. Argentina Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 29. Argentina Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 30. Argentina Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 31. Rest of South America Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 32. Rest of South America Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 33. Rest of South America Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 34. Rest of South America Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 35. Asia Pacific Diabetes Insulin Pen, by Country USD Million (2016-2021)
  • Table 36. Asia Pacific Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 37. Asia Pacific Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 38. Asia Pacific Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 39. Asia Pacific Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 40. China Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 41. China Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 42. China Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 43. China Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 44. Japan Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 45. Japan Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 46. Japan Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 47. Japan Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 48. India Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 49. India Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 50. India Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 51. India Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 52. South Korea Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 53. South Korea Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 54. South Korea Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 55. South Korea Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 56. Taiwan Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 57. Taiwan Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 58. Taiwan Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 59. Taiwan Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 60. Australia Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 61. Australia Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 62. Australia Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 63. Australia Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 68. Europe Diabetes Insulin Pen, by Country USD Million (2016-2021)
  • Table 69. Europe Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 70. Europe Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 71. Europe Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 72. Europe Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 73. Germany Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 74. Germany Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 75. Germany Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 76. Germany Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 77. France Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 78. France Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 79. France Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 80. France Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 81. Italy Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 82. Italy Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 83. Italy Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 84. Italy Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 85. United Kingdom Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 86. United Kingdom Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 87. United Kingdom Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 88. United Kingdom Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 89. Netherlands Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 90. Netherlands Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 91. Netherlands Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 92. Netherlands Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 93. Rest of Europe Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 94. Rest of Europe Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 95. Rest of Europe Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 96. Rest of Europe Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 97. MEA Diabetes Insulin Pen, by Country USD Million (2016-2021)
  • Table 98. MEA Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 99. MEA Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 100. MEA Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 101. MEA Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 102. Middle East Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 103. Middle East Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 104. Middle East Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 105. Middle East Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 106. Africa Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 107. Africa Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 108. Africa Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 109. Africa Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 110. North America Diabetes Insulin Pen, by Country USD Million (2016-2021)
  • Table 111. North America Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 112. North America Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 113. North America Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 114. North America Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 115. United States Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 116. United States Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 117. United States Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 118. United States Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 119. Canada Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 120. Canada Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 121. Canada Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 122. Canada Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 123. Mexico Diabetes Insulin Pen, by Type USD Million (2016-2021)
  • Table 124. Mexico Diabetes Insulin Pen, by Indication USD Million (2016-2021)
  • Table 125. Mexico Diabetes Insulin Pen, by Distribution Channel USD Million (2016-2021)
  • Table 126. Mexico Diabetes Insulin Pen, by End user USD Million (2016-2021)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Diabetes Insulin Pen: by Type(USD Million)
  • Table 138. Diabetes Insulin Pen Disposable pen , by Region USD Million (2022-2027)
  • Table 139. Diabetes Insulin Pen Reusable pen , by Region USD Million (2022-2027)
  • Table 140. Diabetes Insulin Pen Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens} , by Region USD Million (2022-2027)
  • Table 141. Diabetes Insulin Pen: by Indication(USD Million)
  • Table 142. Diabetes Insulin Pen Type 1 Diabetes , by Region USD Million (2022-2027)
  • Table 143. Diabetes Insulin Pen Type 2 Diabetes , by Region USD Million (2022-2027)
  • Table 144. Diabetes Insulin Pen: by Distribution Channel(USD Million)
  • Table 145. Diabetes Insulin Pen Online Pharmacies , by Region USD Million (2022-2027)
  • Table 146. Diabetes Insulin Pen Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 147. Diabetes Insulin Pen Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 148. Diabetes Insulin Pen Diabetes Clinics , by Region USD Million (2022-2027)
  • Table 149. Diabetes Insulin Pen Others , by Region USD Million (2022-2027)
  • Table 150. Diabetes Insulin Pen: by End user(USD Million)
  • Table 151. Diabetes Insulin Pen Geriatric population , by Region USD Million (2022-2027)
  • Table 152. Diabetes Insulin Pen Youth , by Region USD Million (2022-2027)
  • Table 153. Diabetes Insulin Pen Children , by Region USD Million (2022-2027)
  • Table 154. South America Diabetes Insulin Pen, by Country USD Million (2022-2027)
  • Table 155. South America Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 156. South America Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 157. South America Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 158. South America Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 159. Brazil Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 160. Brazil Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 161. Brazil Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 162. Brazil Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 163. Argentina Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 164. Argentina Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 165. Argentina Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 166. Argentina Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 167. Rest of South America Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 168. Rest of South America Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 169. Rest of South America Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 170. Rest of South America Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 171. Asia Pacific Diabetes Insulin Pen, by Country USD Million (2022-2027)
  • Table 172. Asia Pacific Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 173. Asia Pacific Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 174. Asia Pacific Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 175. Asia Pacific Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 176. China Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 177. China Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 178. China Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 179. China Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 180. Japan Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 181. Japan Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 182. Japan Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 183. Japan Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 184. India Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 185. India Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 186. India Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 187. India Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 188. South Korea Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 189. South Korea Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 190. South Korea Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 191. South Korea Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 192. Taiwan Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 193. Taiwan Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 194. Taiwan Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 195. Taiwan Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 196. Australia Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 197. Australia Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 198. Australia Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 199. Australia Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 204. Europe Diabetes Insulin Pen, by Country USD Million (2022-2027)
  • Table 205. Europe Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 206. Europe Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 207. Europe Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 208. Europe Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 209. Germany Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 210. Germany Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 211. Germany Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 212. Germany Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 213. France Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 214. France Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 215. France Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 216. France Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 217. Italy Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 218. Italy Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 219. Italy Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 220. Italy Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 221. United Kingdom Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 222. United Kingdom Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 223. United Kingdom Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 224. United Kingdom Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 225. Netherlands Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 226. Netherlands Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 227. Netherlands Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 228. Netherlands Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 229. Rest of Europe Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 230. Rest of Europe Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 231. Rest of Europe Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 232. Rest of Europe Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 233. MEA Diabetes Insulin Pen, by Country USD Million (2022-2027)
  • Table 234. MEA Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 235. MEA Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 236. MEA Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 237. MEA Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 238. Middle East Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 239. Middle East Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 240. Middle East Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 241. Middle East Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 242. Africa Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 243. Africa Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 244. Africa Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 245. Africa Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 246. North America Diabetes Insulin Pen, by Country USD Million (2022-2027)
  • Table 247. North America Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 248. North America Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 249. North America Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 250. North America Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 251. United States Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 252. United States Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 253. United States Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 254. United States Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 255. Canada Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 256. Canada Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 257. Canada Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 258. Canada Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 259. Mexico Diabetes Insulin Pen, by Type USD Million (2022-2027)
  • Table 260. Mexico Diabetes Insulin Pen, by Indication USD Million (2022-2027)
  • Table 261. Mexico Diabetes Insulin Pen, by Distribution Channel USD Million (2022-2027)
  • Table 262. Mexico Diabetes Insulin Pen, by End user USD Million (2022-2027)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetes Insulin Pen: by Type USD Million (2016-2021)
  • Figure 5. Global Diabetes Insulin Pen: by Indication USD Million (2016-2021)
  • Figure 6. Global Diabetes Insulin Pen: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Diabetes Insulin Pen: by End user USD Million (2016-2021)
  • Figure 8. South America Diabetes Insulin Pen Share (%), by Country
  • Figure 9. Asia Pacific Diabetes Insulin Pen Share (%), by Country
  • Figure 10. Europe Diabetes Insulin Pen Share (%), by Country
  • Figure 11. MEA Diabetes Insulin Pen Share (%), by Country
  • Figure 12. North America Diabetes Insulin Pen Share (%), by Country
  • Figure 13. Global Diabetes Insulin Pen share by Players 2021 (%)
  • Figure 14. Global Diabetes Insulin Pen share by Players (Top 3) 2021(%)
  • Figure 15. Global Diabetes Insulin Pen share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 19. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Medtronic (Ireland) Revenue: by Geography 2021
  • Figure 21. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 22. Novo Nordisk (Denmark) Revenue: by Geography 2021
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2021
  • Figure 25. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Becton, Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 27. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 28. Biocon (India) Revenue: by Geography 2021
  • Figure 29. Diamesco (South Korea) Revenue, Net Income and Gross profit
  • Figure 30. Diamesco (South Korea) Revenue: by Geography 2021
  • Figure 31. Emperra (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Emperra (Germany) Revenue: by Geography 2021
  • Figure 33. Guangzhou Medsinglong Medical Equipment (China) Revenue, Net Income and Gross profit
  • Figure 34. Guangzhou Medsinglong Medical Equipment (China) Revenue: by Geography 2021
  • Figure 35. HK Zion Industry (China) Revenue, Net Income and Gross profit
  • Figure 36. HK Zion Industry (China) Revenue: by Geography 2021
  • Figure 37. Global Diabetes Insulin Pen: by Type USD Million (2022-2027)
  • Figure 38. Global Diabetes Insulin Pen: by Indication USD Million (2022-2027)
  • Figure 39. Global Diabetes Insulin Pen: by Distribution Channel USD Million (2022-2027)
  • Figure 40. Global Diabetes Insulin Pen: by End user USD Million (2022-2027)
  • Figure 41. South America Diabetes Insulin Pen Share (%), by Country
  • Figure 42. Asia Pacific Diabetes Insulin Pen Share (%), by Country
  • Figure 43. Europe Diabetes Insulin Pen Share (%), by Country
  • Figure 44. MEA Diabetes Insulin Pen Share (%), by Country
  • Figure 45. North America Diabetes Insulin Pen Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli Lilly and Company (United States)
  • Medtronic (Ireland)
  • Novo Nordisk (Denmark)
  • Sanofi (France)
  • Becton, Dickinson and Company (United States)
  • Biocon (India)
  • Diamesco (South Korea)
  • Emperra (Germany)
  • Guangzhou Medsinglong Medical Equipment (China)
  • HK Zion Industry (China)
Additional players considered in the study are as follows:
Jiangsu Delfu Medical Device (China) , Owen Mumford (United Kingdom) , Shanghai Umitai Medical Technology (China) , SUN MEDICAL CO., LTD (Japan) , Suzhou Peng Ye Medical Technology Co., Ltd. (China) , Triones Technology (India) , Ypsomed (Switzerland)
Select User Access Type

Key Highlights of Report


Jul 2022 247 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetes Insulin Pen Quantitative research analysis
Global Diabetes Insulin Pen Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Diabetes Insulin Pen study can be customized to meet your requirements. The market size breakdown by type [Disposable pen, Reusable pen and Smart Insulin Pens Caps {First Generation Pens, Second Generation Pens}], by end use application [].
The Diabetes Insulin Pen Market is gaining popularity and expected to see strong valuation by 2027.
  • Increasing Number of Diabetic 2 Prevalence has Been Rising the Need for Insulin Administration.

Know More About Global Diabetes Insulin Pen Report?

Have a Query? Click Here

Other Related Reports

Laboratory Consumables Packaging Comprehensive Study by Type (Vials, Tubes, Pipettes, Burettes, Flasks, Petri Dishes, Beakers, Closures), Application (Healthcare Industry, Pharmaceutical Industry, Fo...
$ 3650
Healthcare Business Intelligence Comprehensive Study by Type (Predictive Analytics, Centralization of Electronic Health Records, Personal Health Apps and Devices, The Social Media Wave), Application ...
$ 3750
Pharmacy Information Systems Comprehensive Study by Type (Inpatient Pharmacy Information Systems, Outpatient Pharmacy Information Systems), Application (Clinical Guidelines, Clinical Reminders, Drug ...
$ 3750
Clinical Decision Support System Comprehensive Study by Type (Integrated CDSS, Standalone CDSS), Application (Conventional CDSS, Advanced CDSS), Deployment Mode (On-Premise, Cloud-based), Level of In...
$ 3450
Rheumatology Therapeutics Comprehensive Study by Type (Disease Modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs), Distribution ...
$ 3750
Apoptosis Regulator BAX Comprehensive Study by Type (GM-6, HU-010, LTX-401, Others), Application (Liver Cancer, Melanoma, Stroke, Parkinson's Disease, Others), Therapies (Gene-based therapy, Drug-bas...
$ 3350